Poteligeo and Losartan drug interactions - a phase IV clinical study of FDA data


Drug interactions are reported among 3 people who take Poteligeo and Losartan.

The phase IV clinical study analyzes what interactions people who take Poteligeo and Losartan have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

What are phase IV trials?

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Sep, 24, 2023

3 people who take Poteligeo and Losartan together, and have interactions are studied.

What is Poteligeo?

Poteligeo has active ingredients of mogamulizumab-kpkc. Currently, eHealthMe is studying from 1,128 Poteligeo users.

What is Losartan?

Losartan has active ingredients of losartan potassium. It is used in high blood pressure. Currently, eHealthMe is studying from 164,729 Losartan users.

Number of Poteligeo and Losartan reports submitted per year:

Poteligeo and Losartan drug interactions.

* Approximation only. Some reports may have incomplete information.

Do you take Poteligeo and Losartan?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Common Losartan side effects:

Browse all side effects of Losartan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Losartan interactions:

Browse all interactions between Losartan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on mogamulizumab-kpkc and losartan potassium (the active ingredients of Poteligeo and Losartan, respectively), and Poteligeo and Losartan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Poteligeo and Losartan.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: